Skip to main content

Advertisement

SpringerLink
Log in

The MUTYH hotspot mutations p.G396D and p.Y179C do not cause substantial genetic susceptibility to biliary cancer

  • Original Article
  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

Inflammation-associated oxidative stress and DNA damage are involved in malignant transformation of cholangiocytes. Defective DNA repair mechanisms may predispose to cholangiocarcinoma (CCA) formation, and an elevated CCA risk for MutY human homologue (MUTYH) germline mutation carriers has been proposed previously. The aim of this study was to re-evaluate the MUTYH hotspot mutations p.Y179C (rs34612342) and p.G396D (rs36053993) as genetic susceptibility factors in a large CCA cohort. The study population consisted of 219 Caucasian CCA patients (66.2 ± 11.9 years, 130 males, 89 females; 43 intrahepatic and 176 extrahepatic tumours; tissue diagnosis in 77.6 %) and 355 healthy controls (61.0 ± 11.0 years; 158 males, 197 females). MUTYH hotspot variants were genotyped using TaqMan assays. Four CCA patients were monoallelic mutation carriers (3 p.G396D; 1 p.Y179C) whereas 6 control subjects were heterozygotes (5 p.G396D; 1 p.Y179C). None of the patients carried a biallelic hotspot mutation. The observed allele frequencies did not differ significantly between cases and controls (p > 0.05) and association tests did not provide evidence for an involvement of p.Y179C (OR 1.6 [95 % CI 0.1–26.0]) or p.G396D (OR 1.0 [95 % CI 0.2–4.1]) in the susceptibility to CCA. Power analysis identified a sufficient power only for large effect sizes (>90 % for OR > 5.8 for p.G396D and OR > 18.5 for p.Y179C). Monoallelic MUTYH hotspot mutations do not act as major genetic susceptibility factors causing a substantial CCA risk in the Caucasian population. Due to the low statistical power for the identification of small effect sizes, much larger studies will be needed to detect such effects of minor clinical significance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shaib Y, El-Serag HB (2004) The epidemiology of cholangiocarcinoma. Semin Liver Dis 24:115–125

    Article  PubMed  Google Scholar 

  2. Cardinale V, Semeraro R, Torrice A, Gatto M, Napoli C, Bragazzi MC, Gentile R, Alvaro D (2006) Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors. World J Gastrointest Oncol 2:407–416

    Article  Google Scholar 

  3. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD (2005) Cholangiocarcinoma. Lancet 366:1303–1314

    Article  PubMed  Google Scholar 

  4. Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, Gaudio E, Alvaro D (2010) Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 42:253–260

    Article  CAS  PubMed  Google Scholar 

  5. Blechacz BR, Gores GJ (2008) Cholangiocarcinoma. Clin Liver Dis 12:131–150

    Article  PubMed  Google Scholar 

  6. Mihalache F, Höblinger A, Grünhage F, Krawczyk M, Gärtner BC, Acalovschi M, Sauerbruch T, Lammert F, Zimmer V (2011) Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma. Aliment Pharmacol Ther 33:389–394

    Article  CAS  PubMed  Google Scholar 

  7. Krawczyk M, Höblinger A, Mihalache F, Grünhage F, Acalovschi M, Lammert F, Zimmer V (2013) Macrophage stimulating protein variation enhances the risk of sporadic extrahepatic cholangiocarcinoma. Dig Liver Dis 45:612–615

    Article  CAS  PubMed  Google Scholar 

  8. Blechacz B, Gores GJ (2008) Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48:308–321

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Braconi C, Patel T (2010) Cholangiocarcinoma: new insights into disease pathogenesis and biology. Infect Dis Clin North Am 24:871–884

    Article  PubMed Central  PubMed  Google Scholar 

  10. Jusakul A, Loilome W, Namwat N, Haigh WG, Kuver R, Dechakhamphu S, Sukontawarin P, Pinlaor S, Lee SP, Yongvanit P (2012) Liver fluke-induced hepatic oxysterols stimulate DNA damage and apoptosis in cultured human cholangiocytes. Mutat Res 731:48–57

    Article  CAS  PubMed  Google Scholar 

  11. Takao M, Aburatani H, Kobayashi K, Yasui A (1998) Mitochondrial targeting of human DNA glycosylases for repair of oxidative DNA damage. Nucleic Acids Res 26:2917–2922

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston A, Williams GT, Hodgkes AK, Davies DR, David SS, Sampson JR, Cheadle JP (2002) Inherited variants of MYH associated with somatic G:C–>T: A mutations in colorectal tumors. Nat Genet 30:227–232

    Article  CAS  PubMed  Google Scholar 

  13. Sieber OM, Lipton L, Crabtree M, Heinimann K, Fidalgo P, Phillips RKS, Bisgaard ML, Orntoft TF, Aaltonen LA, Hodgson DM, Thomas HJW, Tomlinson I (2003) Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 348:791–799

    Article  PubMed  Google Scholar 

  14. Theodoratou E, Campbell H, Tenesa A, Houlston R, Webb E, Lubbe S, Broderick P, Gallinger S, Croitoru EM, Jenkins MA, Win AK, Cleary SP, Koessler T, Pharoah PD, Küry S, Bézieau S, Buecher B, Ellis NA, Peterlongo P, Offit K, Aaltonen LA, Enholm S, Lindblom A, Zhou XL, Tomlinson IP, Moreno V, Blanco I, Capellà G, Barnetson R, Porteous ME, Dunlop MG, Farrington SM (2010) A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer 103:1875–1884

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Mazzei F, Viel A, Bignami M (2013) Role of MUTYH in human cancer. Mutat Res 743–744:33–43

    Article  PubMed  Google Scholar 

  16. Baudhuin LM, Roberts LR, Enders FT, Swanson RL, Mettler TA, Aderca I, Stadheim LM, Highsmith WE (2006) MYH Y165C and G382D mutations in hepatocellular carcinoma and cholangiocarcinoma patients. J Cancer Res Clin Oncol 132:159–162

    Article  CAS  PubMed  Google Scholar 

  17. Win AK, Cleary SP, Dowty JG, Baron JA, Young JP, Buchanan DD, Southey MC, Burnett T, Parfrey PS, Green RC, Le Marchand L, Newcomb PA, Haile RW, Lindor NM, Hopper JL, Gallinger S, Jenkins MA (2011) Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. Int J Cancer 129:2256–2262

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. You SH, Wang X, Huang S, Wang M, Ji GZ, Xia JR, Fan ZN (2013) MYH rs3219476 and rs3219472 polymorphisms and risk of cholangiocarcinoma. Mol Med Rep 7:347–351

    CAS  PubMed  Google Scholar 

  19. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H, British Society of Gastroenterology (2012) Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 61:1657–1669

    Article  CAS  PubMed  Google Scholar 

  20. Casper M, Plotz G, Juengling B, Zeuzem S, Lammert F, Raedle J (2012) MUTYH hotspot mutations in unselected colonoscopy patients. Colorectal Dis 14:e238–e244

    Article  CAS  PubMed  Google Scholar 

  21. Vogt S, Jones N, Christian D, Engel C, Nielsen M, Kaufmann A, Steinke V, Vasen HF, Propping P, Sampson JR, Hes FJ, Aretz S (2009) Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 137:1976–1985

    Article  CAS  PubMed  Google Scholar 

  22. Out AA, Tops CM, Nielsen M, Weiss MM, van Minderhout IJ, Fokkema IF, Buisine MP, Claes K, Colas C, Fodde R, Fostira F, Franken PF, Gaustadnes M, Heinimann K, Hodgson SV, Hogervorst FB, Holinski-Feder E, Lagerstedt-Robinson K, Olschwang S, van den Ouweland AM, Redeker EJ, Scott RJ, Vankeirsbilck B, Grønlund RV, Wijnen JT, Wikman FP, Aretz S, Sampson JR, Devilee P, den Dunnen JT, Hes FJ (2010) Leiden open variation database of the MUTYH gene. Hum Mutat 31:1205–1215

    Article  CAS  PubMed  Google Scholar 

  23. Forsbring M, Vik ES, Dalhus B, Karlsen TH, Bergquist A, Schrumpf E, Bjørås M, Boberg KM, Alseth I (2009) Catalytically impaired hMYH and NEIL1 mutant proteins identified in patients with primary sclerosing cholangitis and cholangiocarcinoma. Carcinogenesis 30:1147–1154

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

We are grateful to Miriam Langhirt for excellent technical assistance.

Conflict of interest

The authors declare that they have no conflicts of interest or financial interests related to the manuscript.

Author information

Authors and Affiliations

  1. Department of Medicine II, Saarland University Medical Center, Kirrberger Straße 100, 66421, Homburg, Germany

    M. Casper, F. Lammert & V. Zimmer

  2. Department of Medicine III, Iuliu Hatieganu University, 400162, Cluj-Napoca, Romania

    M. Acalovschi

Authors
  1. M. Casper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Acalovschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Lammert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Zimmer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Casper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Casper, M., Acalovschi, M., Lammert, F. et al. The MUTYH hotspot mutations p.G396D and p.Y179C do not cause substantial genetic susceptibility to biliary cancer. Familial Cancer 13, 243–247 (2014). https://doi.org/10.1007/s10689-014-9699-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-014-9699-2

Keywords

Search

Navigation